Access requires that you are 21 years of age or older. Products are for laboratory and research use only — not for human or veterinary use, consumption, or clinical application.
Melanotan II reference material, supplied as a lyophilized powder in a sealed vial for in-vitro laboratory research and analytical method development. Each fill size is a separate SKU. Lot and COA records are shown when assigned.
This listing is a research chemical / reference material. No therapeutic, preventive, or diagnostic claims are made or implied. The storefront displays only approved analytical characterization data released through its public report records.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone of 7 amino acids. An analogue of alpha-melanocyte-stimulating hormone.
Cyclic, and non-selective across melanocortin receptor subtypes — the non-selectivity is why development was abandoned.
Reported to activate melanocortin receptors non-selectively. Vectra makes no claim as to mechanism or effect.
First synthesised at the University of Arizona in the late 1980s by Hruby and Hadley. It was never submitted for approval, and pharmaceutical development was abandoned around 2003 because of non-selective receptor activity and off-target effects. Related compounds did reach approval: bremelanotide (PT-141) and afamelanotide. First described by Hruby and Hadley, University of Arizona (Late 1980s).
Studied in melanocortin receptor signalling and pigmentation. A Phase 2 vitiligo trial is recruiting (NCT07437560). Vectra supplies it as a reference material for in-vitro laboratory research and analytical method development only.
Low to moderate. Health utility scored 1 of 10, with a stated verdict of SKIP. Only four to five small human trials exist, all from one University of Arizona group between 1996 and 2000, with a combined N under 70. There has been no independent replication in roughly 28 years and no Phase 3 trial. Approved alternatives exist for every indication it is used for.
Dose-limiting nausea, flushing and fatigue are prominent. There are multiple case reports of cutaneous melanoma, oral mucosal melanoma, and eruptive atypical nevi. One observational cohort of 89 continuous users of more than two years recorded 12 subsequent melanoma diagnoses. That is not established as causal, against a 2–3% baseline lifetime risk. No long-term epidemiology exists to quantify the real risk.
Lyophilised: stable at -20°C for up to two years, or at 2–8°C for three to six months. In solution: stable refrigerated only, 30 days maximum, protected from light.
Our sources carry no CAS number, formula, or sequence for Melanotan II.
Not approved by FDA, EMA, MHRA or Health Canada. FDA 503A Category 2, and specifically excluded from the February 2026 reclassification, so it cannot be compounded. Australia's TGA reclassified it to Schedule 9 (prohibited) in February 2026, citing 89 adverse-event reports between 2022 and 2025 including two melanoma cases. Prohibited at all times by WADA under S2. No therapeutic, preventive, or diagnostic claims are made or implied.
Yes — in more than one way:
Not approved as a medicinal product in any jurisdiction. Current FDA position: Nominated; scheduled for review. Pending advisory review. Vectra supplies this material as a research-use-only reference material. No therapeutic, preventive, or diagnostic claims are made or implied.
FDA has indicated Melanotan II will be reviewed at a Pharmacy Compounding Advisory Committee meeting before the end of February 2027. The votes are advisory and not binding. FDA makes the final determination, and inclusion requires proposed and final rulemaking, with formal approval by the Secretary of Health and Human Services. None of the six is legal to compound on the strength of the vote alone; reporting at the time put the earliest realistic timeline at roughly twelve months.
These are the specific, documented failure modes that lot-level third-party analysis addresses. A report reachable from the lot code printed on the vial — without asking the seller for it — is the only document that answers 'is this vial what the label says'. That is why every Vectra vial carries a QR code resolving to its own lot's published report.
Findings reported by commercial testing providers. Each names its source; none is registry- or peer-review-grade, so read them as a documented pattern rather than established prevalence.
Yes, and altered certificates have been reported in this market at material rates — see the testing findings above. Three properties make a report hard to fake:
Peptide identity data in the vendor market is often wrong in ways that are hard to see. Near-identical compounds get their CAS numbers, residue ranges, formulas and molecular weights swapped. A certificate can be internally consistent and still describe a different molecule than the label names. Most commercial peptide material ships as an acetate salt, not free base. The two forms have different measured masses, so a figure quoted against the wrong one will not reconcile. A report that does not state which form it assayed cannot be checked at all.
The standard our own reports are built to meet:
FDA has acted in this market between 2024 and 2026. Actions include a civil forfeiture over $1.7 million against a compounding operation, several rounds of warning letters to peptide vendors, and more than thirty letters in March 2026 concerning compounded GLP-1 products.
Buyers here increasingly compare document trail, not price.